Episode Details
Back to EpisodesVeru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market
Season 2
Episode 92
Published 6 months, 1 week ago
Description
We welcome back Veru's CEO Mitch Steiner to our latest WTR Small-Cap Spotligh podcast. In this podcast, Steiner gives us his thoughts on the latest trends in the rapidly evolving GLP-1 market for weight loss, discusses the data from enobosarm's Phase 2b data, and explains Veru's obesity drug development strategy in the wake of its recent positive interactions with the FDA.